About this trial
In 2019, the number of patients with diabetes was about 463 million in the world, accounting for 8.3% of the total population, and it is expected to rise to 578 million (9.2%) by 2030 and 700 million (9.6%) by 2045. According to the WHO diagnostic criteria, the prevalence of diabetes among adults in China from 2015 to 2017 was 11.2%, of which over 90% were type 2 diabetes mellitus (T2DM). The global prevalence of non-alcoholic fatty liver disease (NAFLD) is also very high, which was approximately 25% in 2016. The prevalence of NAFLD may continue to rise. NAFLD is often accompanied by clinical manifestations of metabolic syndrome, such as obesity, T2DM, hyperlipidemia and hypertension.
Eligibility criteria
Qualifiers
Diagnosed as T2DM according to the Chinese Guidelines for the Prevention and Treatment of Type 2 Diabetes
UAP were measured based on iLivTouch
Willing to attend this study and able to provide the written informed consent.
Disqualifiers
Other types of diabetes
Patients unable to receive regular follow-up
Trial design
Treatments tested in this trial
- Ultrasound attenuation parameter measurement, fasting blood glucose and fasting insulin determination
Treatment groups
Sponsors and collaborators
Wuxi Hisky Medical Technology Co Ltd
Lead sponsor
Zhongda Hospital
Collaborator
Suzhou Municipal Hospital
Collaborator
Suzhou Fifth People's Hospital
Collaborator
Xuzhou Mining Group General Hospital
Collaborator
Nantong First People's Hospital
Collaborator
Changzhou Second People's Hospital
Collaborator
Huaian Second People's Hospital
Collaborator
Huaian Hospital
Collaborator
Taizhou Jiangyan Traditional Chinese Medicine Hospital
Collaborator
Yangzhou Jiangdu People's Hospital
Collaborator
Huaian Xuyi County People's Hospital
Collaborator